EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges

Michele Nardella, Marco Pellegrini iD, Angeli Christy Yu iD, Ginevra Giovanna Adamo, Marco Mura, Massimo Busin iD

Biomolecules · 2025

DOI: 10.3390/biom15111592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Michele Nardella und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy. Hauptthemen laut MEDLINE: Retinal Pigment Epithelium, Drug Delivery Systems, Nanotechnology. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The retinal pigment epithelium (RPE) is essential for maintaining retinal integrity, and its dysfunction underlies several progressive ocular diseases, including age-related macular degeneration, choroidal neovascularization (CNV), inherited retinal disorders (IRDs), and proliferative vitreoretinopathy (PVR). Although current therapies have improved disease management, they mainly target secondary pathological mechanisms and do not directly preserve or restore RPE function. Moreover, the delivery of therapeutic molecules or genes to the RPE remains a major challenge due to the presence of multiple ocular barriers and the need for sustained, localized action. Nanomedicine offers innovative solutions to these limitations by enabling precise, controlled, and cell-specific delivery of drugs and genetic materials. Engineered nanocarriers can be optimized to traverse ocular barriers, enhance bioavailability, and modulate the retinal microenvironment. This review summarizes recent advances in nanoscale delivery systems for RPE-targeted therapies, focusing on design principles, targeting strategies, and therapeutic applications, and discusses the translational challenges that must be addressed to bring nanotechnology-based treatments closer to clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal Pigment EpitheliumDrug Delivery SystemsNanotechnologyHumansAnimalsTranslational Research, BiomedicalNanomedicineMacular DegenerationRetinal DiseasesNanoparticles

Stichwörter der Autor:innen

age-related macular degenerationdrug deliverygene therapynanotechnologyretinal pigment epithelium

Autor:innen und Institutionen

  • Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
  • Department of Ophthalmology, Ospedali Privati Forlì "Villa Igea", 47122 Forlì, Italy.
  • Ophthalmology Clinic Operating Unit, Head and Neck Department, Sant'Anna University Hospital, 44124 Ferrara, Italy.
  • Istituto Internazionale per la Ricerca e Formazione in Oftalmologia (IRFO), 47122 Forlì, Italy.
  • Department of Vitreoretinal and Uveitis Divisions, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia.

ORCID-Profile: Marco Pellegrini, Angeli Christy Yu, Massimo Busin

Zitieren

APA

Nardella, M., Pellegrini, M., Yu, A. C., Adamo, G. G., Mura, M., & Busin, M. (2025). Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges. Biomolecules. https://doi.org/10.3390/biom15111592

Vancouver

Nardella M, Pellegrini M, Yu AC, Adamo GG, Mura M, Busin M. Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges. Biomolecules. 2025. doi:10.3390/biom15111592

BibTeX
@article{Nardella2025,
  author = {Nardella, Michele and Pellegrini, Marco and Yu, Angeli Christy and Adamo, Ginevra Giovanna and Mura, Marco and Busin, Massimo},
  title = {Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15111592}
}
Kostenlos starten →